gaming controller under 500
The General Secretary of the New Patriotic Party (NPP), Justin Kodua, has expressed confidence in his party’s chances of winning the 2024 elections, despite what he described as a low voter turnout across the country. In a press briefing on Saturday, Kodua emphasized the need for heightened vigilance as the election enters its final stages, particularly during the vote counting process. Kodua acknowledged that the turnout in all 16 regions has been lower than expected, with participation averaging between 50-65%. However, he reassured NPP supporters that the party is on track for victory, citing the party’s ongoing efforts to monitor the election process closely. “I want to assure our teeming supporters that the New Patriotic Party is winning this election. What is left now is for our agents to be vigilant as we approach the counting stage,” Kodua said. He urged party agents, especially those in the Volta Region, to continue their efforts in ensuring that the election process remains fair and transparent. Kodua stressed the importance of every Ghanaian casting their vote, highlighting the significance of the democratic process. He also commended NPP agents for their vigilance in policing polling stations and ensuring that the election was conducted without interference. “We are not there yet. We are entering the stage where the votes will be counted, and it is crucial that we remain alert. Let us not sleep on our watch; we must ensure that the accurate votes are counted,” he added. Kodua also took the opportunity to issue a warning to the Electoral Commission (EC), calling for professional conduct from the commission’s staff during the final stages of the election. His comments reflect growing concerns over the integrity of the election process as it nears its conclusion. As the election moves towards the final stages, Kodua’s remarks underscore the NPP’s commitment to monitoring the process closely and ensuring a transparent and credible outcome.Santa's Sleigh Runs on Magic - But It's Telematics That Keep It Efficient and SustainableUSA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News Group
A modern version of The Skins Game is returning to Thanksgiving week. Pro Shop, the new golf media company led by "Full Swing" executive producer Chad Mumm, on Thursday announced a deal with the PGA Tour that brings back The Skins Game for the first time since 2008. It will be held on Black Friday after Thanksgiving in 2025, an example of more collaboration with the PGA Tour to showcase its best players away from the traditional presentation of golf. Still to be determined are the meat of the details -- who's playing, for how much, and where. The Skins Game was the cornerstone of what once was known as the "silly season" in golf. It began in 1983 with , , and (Vin Scully was the announcer) and held over Thanksgiving weekend in the California desert. A "skin" went to the player who won a hole, and each hole was worth money that increased toward the end of the match. became the face of The Skins Game from winning nearly $4.5 million in 11 appearances. He also had the personality that fit the casual contest. But interest began to wane, even with making occasional appearances. The last Skins Game was in 2008. It lost its title sponsor and the 2009 event was canceled. By then, the PGA Tour had gone to a wraparound season with official tournaments being held right up until Thanksgiving. Mumm joined with Mark Olsen of Vox Media, Joe Purzycki of Puck and David Miller from the PGA Tour to launch Pro Shop, a media, commerce and entertainment company geared toward creating golf content that appeals to a younger audience. Mumm is best known recently for his work with the Netflix docuseries "Full Swing," now approaching its third season. Pro Shop raised nearly $20 million this summer from Powerhouse Capital, the PGA Tour and EP Golf Ventures, among others. It also acquired Skratch, a digital and social media network the PGA Tour created about a decade ago to appeal to a younger audience. "Reimagining an iconic event like The Skins Game in a retro-modern way that engages today's sports fans is exactly why the PGA Tour has partnered with Pro Shop," said Chris Wandell, the senior vice president of media for the PGA Tour. "We look forward to seeing how the newest iteration of the Skins Game unfolds as Pro Shop and Propagate identify cast, format and creative approach."“Wanted” posters with the names and faces of health care executives have been popping up on the streets of New York. Hit lists with images of bullets are circulating online with warnings that industry leaders should be afraid. The apparent targeted killing of UnitedHealthcare CEO Brian Thompson and the menacing threats that followed have sent a shudder through corporate America and the health care industry in particular, leading to increased security for executives and some workers. In the week since the brazen shooting, health insurers have removed information about their top executives from company websites, canceled in-person meetings with shareholders and advised all employees to work from home temporarily. An internal New York Police Department bulletin warned this week that the online vitriol that followed the shooting could signal an immediate “elevated threat.” Police fear that the Dec. 4 shooting could "inspire a variety of extremists and grievance-driven malicious actors to violence," according to the bulletin, which was obtained by The Associated Press. “Wanted” posters pasted to parking meters and construction site fences in Manhattan included photos of health care executives and the words “Deny, defend, depose” — similar to a phrase scrawled on bullets found near Thompson’s body and echoing those used by insurance industry critics. Thompson's wife, Paulette, told NBC News last week that he told her some people had been threatening him and suggested the threats may have involved issues with insurance coverage. Investigators believe the shooting suspect, Luigi Mangione, may have been motivated by hostility toward health insurers. They are studying his writings about a previous back injury, and his disdain for corporate America and the U.S. health care system. Mangione’s lawyer has cautioned against prejudging the case. Mangione, 26, has remained jailed in Pennsylvania, where he was arrested Monday. Manhattan prosecutors are working to bring him to New York to face a murder charge. UnitedHealthcare’s parent company, UnitedHealth Group, said this week it was working with law enforcement to ensure a safe work environment and to reinforce security guidelines and building access policies, a spokesperson said. The company has taken down photos, names and biographies for its top executives from its websites, a spokesperson said. Other organizations, including CVS, the parent company for insurance giant Aetna, have taken similar actions. Government health insurance provider Centene Corp. has announced that its investor day will be held online, rather than in-person as originally planned. Medica, a Minnesota-based nonprofit health care firm, said last week it was temporarily closing its six offices for security reasons and would have its employees work from home. Heightened security measures likely will make health care companies and their leaders more inaccessible to their policyholders, said former Cigna executive Wendell Potter. “And understandably so, with this act of violence. There’s no assurance that this won’t happen again,” said Potter, who’s now an advocate for health care reform. Private security firms and consultants have been in high demand, fielding calls almost immediately after the shooting from companies across a range of industries, including manufacturing and finance. Companies have long faced security risks and grappled with how far to take precautions for high-profile executives. But these recent threats sparked by Thompson's killing should not be ignored, said Dave Komendat, a former security chief for Boeing who now heads his own risk-management company. “The tone and tenor is different. The social reaction to this tragedy is different. And so I think that people need to take this seriously,” Komendat said. Just over a quarter of the companies in the Fortune 500 reported spending money to protect their CEOs and top executives. Of those, the median payment for personal security doubled over the last three years to just under $100,000. Hours after the shooting, Komendat was on a call with dozens of chief security officers from big corporations, and there have been many similar meetings since, hosted by security groups or law enforcement agencies assessing the threats, he said. “It just takes one person who is motivated by a poster — who may have experienced something in their life through one of these companies that was harmful," Komendat said. ___ Associated Press reporters Wyatte Grantham-Philips in New York and Barbara Ortutay in San Francisco, contributed to this report. ___ The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Mount Anthony girls basketball should benefit from some stability
Ravens wide receiver Rashod Bateman and Pro Bowl center Tyler Linderbaum popped up on the team’s penultimate injury report after missing practice Friday in Owings Mills three days ahead of a crucial Monday night showdown against the host Los Angeles Chargers. Bateman, who is second on the team in catches (33) and receiving yards (531) this season, is listed with a knee injury, though he was in good spirits and did not appear to be in pain in the locker room after the snowy session. Linderbaum, meanwhile, missed practice with a back injury, and his backup, rookie Nick Samac (chest), was limited. On the flip side, running back Justice Hill (concussion protocol) and wide receiver Nelson Agholor (illness) were both full participants after Hill was limited a day earlier and Agholor was out sick. The biggest concern for Baltimore (7-4) ahead of its showdown with the Chargers (7-3) remains the status of All-Pro inside linebacker Roquan Smith, who did not practice for a third straight day because of a he suffered in Sunday’s loss to the Pittsburgh Steelers. “It will be a challenge if Roquan can’t go,” defensive coordinator Zach Orr said Friday, adding that Smith’s role will be filled by a committee of Trenton Simpson, Malik Harrison and Chris Board if he doesn’t play. “Not one person is going to replace Roquan. Roquan’s an every-down linebacker [and] a top linebacker in this league [and] All-Pro for a reason. Not one guy’s going to replace him. We like our guys that we have in the room — they’re here for a reason, and somebody [has] to step up.” There were no changes to the rest of the Ravens’ injury report, with safety Kyle Hamilton (neck) and outside linebacker Odafe Oweh (neck) both full participants for a second straight day and defensive tackle Travis Jones (ankle), rookie safety Sanoussi Kane (ankle) and cornerback Arthur Maulet (calf) all not practicing again. The Chargers, on the other hand, appear to be getting healthier with a few key players back at practice. Notably, outside linebackers Khalil Mack (groin) and Joey Bosa (hip), rookie wide receiver Ladd McConkey (shoulder), tight end Hayden Hurst (hip) and rookie cornerback Cam Hart (concussion/ankle) all practiced. Related Articles Mack, who is third on the team with 4 1/2 sacks and hasn’t played since injuring his groin three weeks ago in a win over the Cleveland Browns, practiced for a second straight day, though he was limited again. Bosa, outside linebacker Bud Dupree (foot), safety Derwin James Jr. (groin) and offensive tackle Trey Pipkins III (ankle) were also limited. Mack’s return would be an added boost to a defense that already leads the NFL in points allowed per game (14.5) and is tied for the fourth-most sacks with 34. Meanwhile, McConkey, who leads Los Angeles in catches (43) and receiving yards (615) to go with four touchdowns, was limited after not practicing Thursday, as were Hurst, a 2018 Ravens first-round draft pick, and Hart, a Baltimore native. Linebacker Denzel Perryman (groin) did not practice, nor did former Ravens running back J.K. Dobbins, who was given a rest day. With the game not being until Monday night, the final injury report with game statuses will come out Saturday.Ancient meets modern as a new subway in Greece showcases archaeological treasures THESSALONIKI, Greece (AP) — Thessaloniki, Greece’s second-largest city, is opening a new subway system, blending ancient archaeological treasures with modern transit technology like driverless trains and platform screen doors. The project, which began in 2003, uncovered over 300,000 artifacts, including a Roman-era thoroughfare and Byzantine relics, many of which are now displayed in its 13 stations. Despite delays caused by preserving these findings, the inaugural line has been completed, with a second line set to open next year. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. At least 19 people are sick in Minnesota from ground beef tied to E. coli recall U.S. health officials say at least 19 people in Minnesota have been sickened by E. coli poisoning tied to a national recall of more than 167,000 pounds of potentially tainted ground beef. Detroit-based Wolverine Packing Co. recalled the meat this week after Minnesota state agriculture officials reported multiple illnesses and found that a sample of the product tested positive for E. coli O157:H7, which can cause life-threatening infections. Symptoms of E. coli poisoning include fever, vomiting, diarrhea and signs of dehydration. Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. Actor Jonathan Majors’ ex-girlfriend drops assault and defamation lawsuit against once-rising star NEW YORK (AP) — Jonathan Majors’ ex-girlfriend has dropped her assault and defamation lawsuit against the once-rising Hollywood star after reaching a settlement. Lawyers for Majors and Grace Jabbari agreed to dismiss the case with prejudice Thursday. Jabbari is a British dancer who had accused Majors of subjecting her to escalating incidents of physical and verbal abuse during their relationship. Representatives for Majors didn’t respond to emails seeking comment Friday. Jabbari’s lawyer said the suit was “favorably settled” and her client is moving on with “her head held high.” Majors was convicted of misdemeanor assault and harassment last December and sentenced to a yearlong counseling program. Hyundai, Kia recall over 208,000 electric vehicles to fix problem that can cause loss of power DETROIT (AP) — Hyundai and Kia are recalling over 208,000 electric vehicles to fix a pesky problem that can cause loss of drive power, increasing the risk of a crash. The recalls cover more than 145,000 Hyundai and Genesis vehicles including the 2022 through 2024 Ioniq 5, the 2023 through 2025 Ioniq 6, GV60 and GV70, and the 2023 and 2024 G80. Also included are nearly 63,000 Kia EV 6 vehicles from 2022 through 2024. The affiliated Korean automakers say in government documents that a transistor in a charging control unit can be damaged and stop charging the 12-volt battery. Dealers will inspect and replace the control unit and a fuse if needed. They also will update software. Christmas TV movies are in their Taylor Swift era, with two Swift-inspired films airing this year Two of the new holiday movies coming to TV this season have a Taylor Swift connection that her fans would have no problem decoding. “Christmas in the Spotlight” debuts Saturday on Lifetime. It stars Jessica Lord as the world’s biggest pop star and Laith Wallschleger, playing a pro football player, who meet and fall in love, not unlike Swift and her boyfriend, Kansas City Chiefs tight end Travis Kelce. On Nov. 30, Hallmark will air “Holiday Touchdown: A Chiefs Love Story.” Instead of a nod to Swift, it’s an ode to family traditions and bonding, like rooting for a sports team. Hallmark’s headquarters is also in Kansas City. Top football recruit Bryce Underwood changes commitment to Michigan instead of LSU, AP source says ANN ARBOR, Mich. (AP) — Top football recruit Bryce Underwood has flipped to Michigan after pledging to play at LSU. That's according to a person familiar with the situation who spoke to The Associated Press on condition of anonymity because they were not authorized to share the recruit’s plans to join the Wolverines. Underwood pinned a post on his Instagram account, showing a post in which On3.com reported that he has committed to Michigan. The 6-foot-3 quarterback played at Belleville High School about 15 miles east of Michigan's campus, and told LSU nearly a year ago he intended to enroll there. Emperor penguin released at sea 20 days after waddling onto Australian beach MELBOURNE, Australia (AP) — The only emperor penguin known to have swum from Antarctica to Australia has been released at sea 20 days after he waddled ashore on a popular tourist beach. The adult male was found on Nov. 1 on sand dunes in temperate southwest Australia about 2,200 miles north of the Antarctic coast. He was released Wednesday from a boat that traveled several hours from Western Australia state's most southerly city of Albany. His caregiver Carol Biddulph wasn't sure at first if the penguin would live. She said a mirror was important to his rehabilitation because they provide a sense of company. Biddulph said: “They’re social birds and he stands next to the mirror most of the time.” Shohei Ohtani wins third MVP award, first in NL. Aaron Judge earns second AL honor in 3 seasons NEW YORK (AP) — Shohei Ohtani won his third Most Valuable Player Award and first in the National League, and Aaron Judge earned his second American League honor on Thursday. Ohtani was a unanimous MVP for the third time, receiving all 30 first-place votes and 420 points in voting by the Baseball Writers’ Association of America. New York Mets shortstop Francisco Lindor was second with 263 points and Arizona second baseman Ketel Marte third with 229. Judge was a unanimous pick for the first time. Kansas City shortstop Bobby Witt Jr. got all 30 second-place votes for 270 points, and Yankees outfielder Juan Soto was third with 21 third-place votes and 229 points.Thomas uses big drives and putts to hold lead in Bahamas
MAX George has revealed that he is set to undergo major heart surgery after a terrifying dash to hospital. The singer, 36, posted a photo of himself lying in a hospital bed giving a thumb’s up — and told fans that he considered himself “very lucky”. 4 Max George is set to undergo heart surgery after being rushed to hospital Credit: Instagram 4 The Wanted star said he was diagnosed with a heart condition Credit: Instagram It comes just two years after his Wanted bandmate and best pal Tom Parker died of brain cancer aged just 33. He took to social media on Thursday to share a health update. Max said he was given a “huge shock” when told he had problems with his heart after feeling ill and will be having tests to gauge the extent. He posted online: "Hey everyone. Yesterday I felt really unwell and was taken in to hospital. READ MORE ON MAX GEORGE TRAGIC GOODBYE Heartbroken Max George announces shock death of dog oh mai! Inside Maisie Smith & Max George's romantic Cyprus hol as star stuns in red bikini "Unfortunately after some tests they’ve found that I have some issues with my heart." The TV star, who is dating EastEnders actress Maisie Smith , said he would need surgery before he returns home. "I have a lot more tests to determine the extent of the problems and what surgery I will need to get me back on my feet," he went on to say. Max explained that he would be remaining in hospital over the festive period - but was thankful for the support of his girlfriend and family. Most read in Celebrity FAIR CARNAGE Horror as Birmingham fairground ride 'collapses' with several people injured ALL CHANGE Another Rangers executive quits club just a week after key role at club's AGM NEWBORN JOY Huge Scots DJ becomes dad as he reveals baby boy in emotional social media post URGENT HUNT Fears grow for two boys, 12 and 13, last seen 24 hours ago sparking huge search He shared: "It’s gonna be a difficult few weeks/months... and Christmas in a hospital bed wasn’t exactly what I had planned! "But, as always, I’m surrounded with love and support by my wonderful partner Maisie, her family, my family and friends.. and I’m 100 per cent in the best place." Maisie Smith and Max George reveal they're 'homeless' saying they’re 'forced to go on holiday all the time The pop star added: "Although this is a huge shock and no doubt a set back, it’s something I’ll take on with all I’ve got! I count myself very lucky that this was caught when it was. "Apologies if I bore you with updates in the coming weeks..I’ve probably got a month in a bed and there’s not THAT much to do! "Let’s do this!. Much love. Max x" Maisie and Max both competed in Strictly Come Dancing 2020 and became good friends while on the show. In the summer of 2022, they became a romantic item and they moved in together last year. Maisie waved Essex goodbye and relocated to Manchester to be with Max and they began renovating their own home together. There is a 13-year age gap between the pair but they have always been too loved up to pay attention to any criticism surrounding it. Maisie told The Sun’s Fabulous Magazine in February: "If it wasn’t that, it would be something else. "People don’t understand what goes on behind closed doors in a relationship, and I think they also forget that I’m a consenting 21-year-old woman who’s actually been working longer than Max! "I don’t notice the age difference and neither do my friends or family. My mum Julia is the one who reads through all the comments. I got a message from her yesterday, saying, ‘Just ignore them, you two were made for each other'. "I think that just puts it into perspective. I really don’t care what a random person thinks of my relationship when everyone I do care about is incredibly supportive. I’ve been in the business long enough to know you have to have a thick skin." Max previously told how he suffered from alcoholism — but turned a new leaf after Tom’s devastating diagnosis in 2020. The dad of two died two years later. Max said on Channel 4’s Scared Of The Dark: “I don’t think I’ll ever be OK with it. Read more on the Scottish Sun WARMING UP Scots set for 21C swing as temperature rise to bring an end to sub zero freeze HOT BUY Shoppers race to Primark for fleecy £14 hoodie will keep you cosy on frosty days “One of the last things I said to him was — I thanked him for making my life so much better than what it ever could have been. “He was my best friend.” 4 Max praised his girlfriend Maisie Smith for her support during this time Credit: maisiesmithofficial/Instagram.. 4 The pop star said he will be remaining in hospital over Christmas Credit: instagram/@maxgeorgeFedEx is taking steps to streamline its operations by prioritizing its DRIVE program and separating FedEx Freight into a standalone, publicly traded company. These decisions were announced by FedEx President and CEO Raj Subramaniam Thursday (Dec. 19) during the company’s second-quarter earnings call, which saw the company’s total sales of $22 billion slip 1%. Amid these challenges, Subramaniam highlighted the ongoing success of FedEx’s DRIVE program, which he said is critical to the company’s operational improvements. Originally conceived as a structural cost optimization initiative, DRIVE has grown into a broader strategy that fosters efficiency and enhances decision-making across the business. DRIVE: A Catalyst for Growth “I’ve talked about DRIVE as our structural cost optimization program,” Subramaniam said to analysts. “The reality is that within FedEx, DRIVE has evolved to be so much more. It’s a new data and technology driven business architecture that has changed how we work across our entire enterprise, introducing more rigor and accountability to every decision we make, leading to a continuous cycle of efficiency and optimization. ” DRIVE, he added, “has clearly evolved to be how we work in this company. We have established an overarching market-leading approach to overall governance that leads to disciplined execution. This is going to stand us in good stead as a foundation for FedEx to execute as we go forward. The second thing is we also adopted a data-first digital mindset in solving problems while creating differentiation in our service offerings. The underlying technological innovation and transformation that we have created is quite profound.” The challenges faced during the quarter, including a soft global industrial economy and competitive pricing pressures, were closely linked to the need for continuous improvements, particularly through DRIVE’s data-driven approach to cost management, according to Chief Financial Officer John Dietrich . “We remain confident in our ability to offset these headwinds with the $2.2 billion from incremental DRIVE savings,” Dietrich said. “This expectation further highlights how DRIVE is fundamentally changing the way we do business. We’re improving our cost structure to enable us to profitably grow with eCommerce and are well-positioned to see significant incremental margins on our priority services once global industrial production improves.” FedEx Freight’s Separation and Future Outlook During the earnings call, FedEx also announced its decision to fully separate FedEx Freight, creating two publicly traded companies. This move aims to unlock value for shareholders while allowing the two businesses to remain strategically aligned, Subramaniam said. Each company will be able to sharpen its focus and competitiveness, better executing its priorities while continuing to invest in growth and return capital to shareholders. Each company will benefit from enhanced focus and competitiveness, he added, allowing them to execute their strategic priorities and continue investing in profitable growth while returning capital to shareholders. “We’re excited to create a leading LTL [less than truckload] pure-play, the largest carrier by revenue with the broadest network and the fastest transit times,” Subramaniam said. “FedEx Freight has deep relationships with customers who turn to us for our reliability, simplicity and choice of services. Freight has maintained its leading market share position for a long time and increased operating profit nearly 25% on average per year over the last five years.” As a separate company, Freight will be better positioned to unlock its full value potential, Subramaniam added. “Areas where we see the greatest opportunity include: first, an expanded dedicated LTL sales force led by Tom Connolly, our new VP of LTL Sales, who has nearly 30 years of experience,” he said. “We’ve already begun to build out this team and we expect to add more than 300 LTL specialists by the time of separation. “Second, an enhanced LTL-specific pricing and invoicing system that drives faster speed to market, more intuitive contracts and is more tailored to this market,” he added. “Third, improved Freight and FedEx network efficiencies focused on accelerating speed, improving coverage, optimizing touches and lowering our cost to serve. “And four, an LTL-focused automation, which will drive efficiency and reduce outside vendor spend. FedEx Freight’s portfolio of solutions, which includes both priority and economy services, is also well-positioned to benefit from the long-term market dynamics shaping the LTL industry,” Subramaniam said.
Shares of Deerfield Healthcare Technology Acquisitions Corp. ( OTCMKTS:DFHTU – Get Free Report ) traded down 2.2% during mid-day trading on Friday . The company traded as low as $15.56 and last traded at $15.65. 600 shares were traded during trading, a decline of 93% from the average session volume of 9,052 shares. The stock had previously closed at $16.00. Deerfield Healthcare Technology Acquisitions Stock Performance The firm’s 50-day simple moving average is $15.65 and its two-hundred day simple moving average is $15.65. Deerfield Healthcare Technology Acquisitions Company Profile ( Get Free Report ) Deerfield Healthcare Technology Acquisitions Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare or healthcare-related industries in the United States and other developed countries. Read More Receive News & Ratings for Deerfield Healthcare Technology Acquisitions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deerfield Healthcare Technology Acquisitions and related companies with MarketBeat.com's FREE daily email newsletter .Nvidia’s Project Denver began as x86 but transitioned to Arm Insider reports legal constraints drove Nvidia's pivot The Arm-based Project Denver CPU debuted in 2011 During a technical session at the recent SC24 event, Dave Ditzel, founder of Esperanto Technologies, offered some fascinating insights into Nvidia ’s early server processor efforts. According to HPCwire , Ditzel, who was previously CEO of Transmeta, revealed that Nvidia’s first server CPU, Project Denver , initially started as an x86 CPU but transitioned to Arm due to legal constraints. Ditzel says Nvidia’s shift to Arm was influenced by its licensing of Transmeta’s Tokamak technology, which could translate x86 code into a RISC instruction set. Failed attempt to acquire Arm IAs he explained, “Nvidia brought out a product called Denver. It was actually that same design. It originally started as an x86 [CPU], but through certain legal issues, had to turn itself into an Arm CPU.” This decision, he said, laid the foundation for Nvidia’s alignment with Arm architecture. Tokamak, developed by Transmeta, was intended to be its third-generation x86 chip following the Crusoe and Efficeon processors. However, the project was never officially launched and was instead licensed to companies like Intel and Nvidia. ntel, despite acquiring the design, did not announce a product based on it either. “You can guess as to all the reasons why or buy me a beer sometime,” Ditzel said. Nvidia officially introduced Project Denver as an Arm-based CPU in 2011, later integrating it into its Tegra lineup. HPCwire reports that while there was initial enthusiasm around Arm servers, adoption was limited by challenges in the software ecosystem. Nvidia has since developed its Grace CPU and abandoned its attempt to acquire Arm after regulatory opposition. Are you a pro? Subscribe to our newsletter Sign up to the TechRadar Pro newsletter to get all the top news, opinion, features and guidance your business needs to succeed! Ditzel founded chip design firm Esperanto about seven years ago and because of his previous bad experiences with licensing x86, he opted for RISC-V because it was cheap and there were no legal concerns to get bogged down by. “At least we have a playground where we can test some new things out, and some lawyer is not going to be ringing your bell,” Ditzel said. Nvidia's most powerful chip produced gets tested This 192-core RISC-V processor could be AMD and Intel's biggest rival yet Google's super powerful Arm-based CPU is now available